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ObjectiveaaGene variants within the serotonin pathway have been associated with major depressive disorder (MDD) treatment out-
comes, however a possible different modulation on pharmacological or psychological treatments has never been investigated.
MethodsaaOne hundred sixty MDD patients were partially randomized to either inter-personal counseling (IPC) or antidepressants. 
The primary outcome was remission at week 8. Five serotonergic polymorphisms were investigated (COMT rs4680, HTR1A rs6295, 
HTR2A rs2224721, HTR2A rs7997012 and SLC6A4 rs421417).
ResultsaaIPC (n=43) and antidepressant (n=117) treated patients did not show any difference in remission rates at week 8 (corrected 
for baseline severity, age and center). None of the studied gene variants impacted on response and remission rates at week 8 neither in the 
IPC nor in the antidepressant group. An analysis of the whole sample showed a trend of association between rs7997012 AA genotype and 
a better treatment outcome.
ConclusionaaOur study confirms that IPC is an effective psychological intervention comparable to antidepressants in mild-moderate 
MDD. Polymorphisms related to the serotonin system did not exert a major effect on clinical outcomes in none of the treatment groups.
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INTRODUCTION
Major depressive disorder (MDD) is the most common psy-
chiatric disorder (life-time prevalence: 12.8%), and it is re-
sponsible for the great burden linked to non-fatal health out-
comes.1 After the introduction of antidepressant drugs in the 
’50, no substantial improvement in MDD clinical manage-
ment was achieved, given the still unsatisfactory response and 
remission rates [47 and 33%, respectively, in the large Se-
quenced Treatment Alternatives to Relieve Depression (ST-
AR*D) cohort].2 Nowadays, together with the introduction of 
innovative antidepressant molecules, the identification of reli-
able predictors of treatment response for the each subject is 
expected in order to provide a substantial improvement of 
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MDD prognosis. 
Among treatment options, selective serotonin reuptake in-
hibitors (SSRIs) are the first line treatment and psychological 
interventions such as inter-personal counseling (IPC) have 
been suggested to have comparative efficacy and effectiveness 
when compared to antidepressants (response rates are from 
30% to 50% regardless the choice of pharmacotherapy or psy-
chotherapy),3 particularly in moderate MDD. Combined tr-
eatment may provide a small advantage (with effect size esti-
mated from 0.25 to 0.35), even if it does not seem to persist 
during medium-long follow-up and not to be significant in 
mild MDD.4 However no clear guideline is available to choose 
the best treatment in each patient, even if some clinical pre-
dictors of IPC vs. antidepressant pharmacotherapy efficacy 
have been proposed.5 Thus, further evidence is needed to bet-
ter clarify the efficacy of brief psychotherapies vs pharmaco-
logical treatments and to identify reliable predictors of clinical 
outcomes.
Among predictors of treatment response, genetic factors are 
estimated to contribute for a substantial degree to the interin-
dividual variability.6 Given that monoamines are pivotal in an-
tidepressant response,7 genes related to the serotoninergic sys-
tem are considered among the most promising candidates. 
Particularly, serotonin receptors, serotonin transporter and 
enzymes responsible for the metabolism of monoamines are 
involved in the regulation of the serotoninergic neurotrans-
mission in the CNS. 
The serotonin 2A receptor (coded by HTR2A gene) is ex-
pressed in all neocortical areas, in putative interneurons, hip-
pocampus and prefrontal cortex.8 It is down-regulated by dif-
ferent classes of antidepressants in parallel with the improve-
ment of clinical symptoms9 and some interesting polymor-
phisms were reported within HTR2A. Particularly, rs7997012 
was strongly associated with citalopram response in the 
STAR*D study,10,11 even if other studies obtained inconsistent 
findings (negative results12-16 in the opposite direction17 or as-
sociation only when considering the interaction with gen-
der18). Rs2224721 harbored by the same gene was associated 
with the risk of bipolar disorder19 and was one of the two best 
predictors of escitalopram response in the GENDEP (Ge-
nome-based Therapeutic Drugs for Depression) sample,14 
suggesting it as a promising target for further investigation. 
A role of the HTR1A gene in antidepressant response has 
also been postulated because several antidepressants desensi-
tize raphe 5-HT1A autoreceptors, leading to an enhancement 
of the 5-HT neurotransmission. Moreover there is evidence 
that the blockade of 5-HT1A autoreceptors may accelerate 
antidepressant effect.6 The most promising SNP within the 
gene is the rs6295 (1019C/G), since the G allele was associat-
ed with an up regulation of the expression of the receptor20,21 
leading to the hypothesis that it may contrast the therapeutic 
effect of antidepressants through a higher number of inhibi-
tory 5-HT1A autoreceptors. This hypothesis is supported by 
several pharmacogenetic studies,22-28 while some negative re-
ports exist.16,29-32 Interestingly, an interaction with gender was 
reported for rs629533 as well as for rs7997012. 
The serotonin transporter gene (SLC6A4) is probably the 
leading candidate as predictor of antidepressant response, 
since it codes for one of the main target of antidepressant 
drugs. Polymorphic variants within the promoter have gained 
particular attention, since their supposed effect on gene ex-
pression regulation.6 Research efforts were mainly directed 
towards the study of the insertion/deletion variant (5-HTTL-
PR), and to a less extent, rs25531, but the need to provide a 
better coverage of the region recently emerged. Rs4251417 
harbored by this genomic region was found in linkage dis-
equilibrium with 5-HTTLPR34 and its possible role in antide-
pressant response has not been investigated yet.
Finally, the catechol-O-methyltransferase (COMT) gene 
codes for an intracellular enzyme with a key role in the inacti-
vation of monoamines. Rs4680 (Val108/158Met) is a func-
tional polymorphism which Val/Val genotype catabolizes do-
pamine at up four times the rate of Met/Met homozygote.35 
Given the close interactions between the serotonergic and do-
paminergic systems, dopamine availability in some areas of 
the CNS such as the frontal cortex and the nucleus accum-
bens was reported to modulate antidepressant response.6 
Pharmacogenetic findings about rs4680 mainly confirmed it 
plays a role in antidepressant response,36-41 while which geno-
type/allele is associated with poorer outcome still remains 
unclear.6 A sexually dimorphic effect was reported also for 
this polymorphism.40
The mechanisms behind the antidepressant efficacy of psy-
chotherapy in MDD are less known. The main hypothesis is a 
direct effect on cognitive processes such as dysfunctional atti-
tudes and negative automatic thoughts,42 but the knowledge 
about the molecular processes involved is poor. Anyway, im-
provement of cognitive measures is not different between pa-
tients treated with pharmacotherapy and psychotherapy,43 
suggesting that ultimately common mechanisms mediate the 
efficacy of both therapeutic approaches. This is also supported 
by the evidence of monoamines balance modification during 
psychotherapy, involving in particular serotonin transporter 
activity.44,45
Given the reported unsolved issues, the present paper aims 
to study the role of HTR2A rs7997012 and rs2224721, HTR1A 
rs6295, SLC6A4 rs4251417 and COMT rs4680 on antidepres-
sant efficacy in a sample of 160 MDD Italian patients, treated 
with IPC or antidepressants. No previous study investigated 
the possible effect of these polymorphism on IPC response.
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METHODS
Sample
Patients aged 18 years or older with diagnosis of MDD (ac-
cording to DSM-IV TR criteria), with a score ≥13 on Hamil-
ton Depression Rating Scale (HDRS, 21-item version, in ac-
cordance to STAR*D criteria2), were eligible for inclusion. 
Any other psychiatric disorder as primary diagnosis (bipolar 
disorder included), comorbidity for substance abuse, cogni-
tive impairment (Mini Mental State Evaluation <28), poor 
ability to participate to evaluations and current pregnancy or 
feeding were exclusion criteria. After a baseline assessment, 
eligible patients were partially randomized to a brief struc-
tured psychological intervention (IPC) or to antidepressant 
treatment (mainly SSRIs)(Table 1).46 Patients were collected 
in three centers: 35 were collected at the Neuroscience De-
partment, Turin University, 41 at the Department of Health 
Sciences, Section of Psychiatry, University of Pavia and 84 at 
the Department of Biomedical and NeuroMotor Sciences, 
Bologna University. All patients collected at the Institute of 
Psychiatry, Bologna University were treated with antidepres-
sants and not randomized.
Patients were carefully informed about all study procedures 
before signing written informed consent. Ethical approval 
was obtained from local research ethic committees. 
Interpersonal counseling (IPC)
IPC is a brief manualized psychological intervention, de-
rived from Interpersonal Psychotherapy (IPT). IPC has been 
adapted and tested on patients with depressive disorders, in 
association with pharmacological treatment or alone.47-50 It 
consisted of six thirty-minute sessions, with the initial session 
being longer, and is focused on patients’ current psychological 
problems and social functioning and specifically on four in-
terpersonal problem areas: prolonged grief, interpersonal dis-
putes, role transitions and interpersonal deficits;51 patients are 
helped to identify effective strategies in order to deal with their 
interpersonal problems. To ensure the intervention’s consis-
tency, therapists attended a 3-day teaching seminar on IPC 
techniques and monthly group supervisions with videotaped 
sessions. 
Evaluations
All patients were evaluated with both structured and un-
structured interviews to obtain lifetime diagnoses assigned by 
two independent experienced psychiatrists, on the basis also 
of medical records, according to DSM-IV TR criteria. Cur-
rent and lifetime Axis I and II diagnoses were assessed by 
Mini International Neuropsychiatric Interview (MINI) and 
structured clinical interview for DSM-IV TR Axis II Person-
ality disorders. Cognitive impairment was assessed by Mini 
Mental State Examination (MMSE) in patients older than 60. 
Depressive symptoms were assessed at baseline and after 8 
weeks through HDRS. Interrater evaluations were satisfactory 
(k>0.8).
Outcomes
The primary outcome was remission at week 8, defined ac-
cording to standard criteria (HDRS score ≤7). The second-
ary outcomes were response (at least 50% reduction in HDRS 
score) and HDRS percent improvement at week 8. 
Genotyping
Genomic DNA was purified from whole blood using the 
QIAamp DNA Blood Midi Kit (Qiagen, CA, USA), according 
Table 1. Clinical-demographic characteristics of the whole sample
Variable Value
Gender (F/M) 105/55
Age (mean±SD) 50.71±18.01
Number of previous depressive  
  episodes (mean±SD)
0.89±1.32
Baseline severity (HDRS) 17.97±5.26
Treatment (%) 91 (56.88): SSRIs
18 (11.25): SNRIs
8 (5.00): other antidepressants
43 (26.88): IPC
Employment (%)† 39 (31.20): employed
7 (5.60): housewife
15 (12.00): student
6 (4.80): unemployed
32 (25.60): retired
26 (20.80): other or unknown
Personality disorder (SCIDII)* 4 (3.36): cluster A
19 (15.97): cluster B
9 (7.56): cluster C
5 (4.20): NAS
61 (51.26): none
21 (17.65): unknown
Education (years) (mean±SD) 11.69±4.79
Marital status (%)† 40 (32.00): single
50 (40.00): married
14 (11.20): separated/divorced
14 (11.20): widowed
7 (5.60): unknown
Available genotypes 157
*available for only 2 centers (Bologna and Torino), †available for 
only two centers (Bologna and Pavia). HDRS: Hamilton Depres-
sion Rating Scale 21-items, SCIDII: Structured Clinical Interview 
for DSM IV axis II personality disorders, NAS: non otherwise 
specified, IPC: interpersonal counseling, SD: standard deviation
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to the manufacturer’s protocol. Rs7997012 and rs2224721 
(HTR2A, chr 5q11.2-q13), rs6295 (HTR1A, chr 5q11.2-q13), 
rs4251417 (SLC6A4, chr 17q11.2) and rs4680 (COMT, chr 
22q11.21) were genotyped by High Resolution Melting (HRM) 
-PCR. All the experiments were performed by the Rotor Gene 
Q instrument (Qiagen, CA, USA), using the Type-it HRM PCR 
Kit (Qiagen, CA, USA). The following primers were used for 
PCR amplifications: 
F-5’-GAACGCTGAGTTGATGTAAT-3’ and R-5’-CCACC 
TTCCAAGAATCCT-3’ (rs7997012), F-5’-ACCCAATCAC-
TAAATCCT-3’ and R-5’-GGAAACTAGACCAGTAAAG-3’ 
(rs2224721), F-5’-GCGAGAACGGAGGTAGCTTT-3’ and 
R-5’-GGTCAGTCTCCCAATTATTGCT-3’ (rs6295), F-5’-
CTGAGGACTCCTGAGAAC-3’ and R-5’-CAGAGAGGG-
TAGAAAATGTG-3’ (rs4251417), F-5’-CAGCGGATGGT-
GGATTTC-3’ and R-5’-TTCCAGGTCTGACAACGG-3’ 
(rs4680), all designed by Beacon Designer v. 7.9 (PREMIER 
Biosoft, CA, USA). After an initial step of enzyme activation 
at 95°C for 5 min, PCRs were carried out by 40 cycles as fol-
lows: denaturation at 95°C for 10 sec and annealing at 60°C 
for 30 sec (56°C for rs2224721). The HRM analysis was per-
formed with a temperature resolution of 0.1°C and a tempera-
ture range between 70°C and 85°C. Data collection and geno-
type calls were obtained by the Rotor-Gene 6000 series so-
ftware v. 1.7 (Qiagen, CA, USA) using as reference genotypes 
DNA samples sequenced by the ABI Prism® 310 Genetic An-
alyzer (Applied Biosystems, CA, USA).
Statistical analysis
Chi-squared test, Fisher’s exact test and student’s t test were 
used as appropriate for comparing baseline characteristics 
among treatment groups (Table 2). The effect of genotypes 
and alleles on response and remission rates was estimated 
through Pearson’s chi-squared tests. In order to account for the 
confounding effect of recruitment site and baseline HDRS 
impact on response and remission in the IPC group (Table 2), 
one-way ANOVA was used within a linear regression model 
to study the effect of genotypes and alleles on clinical out-
comes adjusting for the reported variables. Given that a gen-
der-dimorphic effect has been previously reported for three 
of the studied polymorphisms (see Introduction), the possible 
interaction allele x gender was also tested. Only results ob-
tained in the completers group (Table 2) were reported since 
the presence of only two time points of evaluation did not al-
low a reliable application of the last observation carried for-
ward (LOCF) method. Analysis were carried out both in the 
two treatment arms separately and in the whole sample, since 
similar mechanisms are supposed to mediate the antidepres-
sant effect of both treatments.44,45 The level of significance was 
conservatively set to 0.05. R software was used for the analysis 
(cran.r-project.org/). Genotype frequencies were evaluated 
for Hardy-Weinberg equilibrium using Haploview 4.2. Our 
sample setting alpha value to 0.05 two tailed provides a power 
of 0.80 to observe for the whole sample a difference between 
two variants with effect size d=0.26, which corresponds to a 
difference of (at least) 1.5 points in the final HDRS and to an 
explained variance of 2.2%.
RESULTS
The studied polymorphisms did not show any deviation 
from Hardy-Weinberg equilibrium (COMT rs4680: p=0.14; 
HTR1A rs6295: p=0.25; HTR2A rs2224721: p=1; HTR2A 
rs7997012: p=0.62; SLC6A4 rs4251417: p=0.98). 
Clinical-demographic characteristics of the sample were 
reported in Table 1 for the whole sample and in Table 2 for 
Table 2. Clinical characteristics and outcomes at week 8 according to treatment group. Chi-squared and Fisher’s exact tests were used as 
appropriate to test differences between the two treatment groups 
Whole sample (N=145) ICP (N=42) Antidepressants (N=103) Statistics
Response
Yes 93 (64.14%) 26 (61.90%) 67 (65.05%) χ2=0.03, df=1, p=0.87
No 52 (35.86%) 16 (38.10%) 36 (34.95%)
Remission
Yes 91 (62.76%) 29 (69.05%) 62 (60.19%) χ2=0.66, df=1, p=0.42
No 54 (37.24%) 13 (30.95%) 41 (39.81%)
Improvement (%)   54.85±28.61   52.05±19.40   56.01±31.53 t=-0.92, CI=-0.13 - 0.046, p=0.36
HDRS missing at week 8 15 1 14 OR=0.18, CI=0.004 - 1.23, p=0.07
Baseline severity (HDRS) 17.97±5.26 16.33±4.08 18.56±5.48 t=-2.79, CI=-3.83 - -0.65, p=0.006
Age   50.71±18.01   53.24±18.15   43.93±15.93 t=-3.15, CI=-15.20 - -3.43, p=0.002
Gender (F/M) 105/55 25/18 80/37 χ2=1.43, df=2, p=0.49
 CI: 95% confidence interval, IPC: interpersonal counseling, HDRS: Hamilton Depression Rating Scale 21-items
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each treatment group. For 15 patients (9.38%) HDRS was not 
available at week 8 (Table 2), but this group did not show any 
difference in age (47.93±18.17; t=-0.60, CI=-13.85 - 7.75, p= 
0.56), gender (F/M:10/5; chi2=1.04, df=1, p=0.31) and base-
line severity (21.47±9.52; t=1.56, CI=-1.44 - 9.18, p=0.14) 
when compared to the 8 week-completers. Moreover, no dif-
ferent risk of drop-out was found between the ICP and anti-
depressant group, though a trend of better retention was de-
tected in the IPC group (Table 2). No difference was also 
observed in response and remission rates and percent of im-
provement at week 8 between the two treatment groups (Ta-
ble 2), also adjusting for age, baseline severity and center (re-
sponse: F=0.19, df=1, p=0.66; remission: F=1.15, df=1, p= 
0.29; % improvement: F=0.59, df=1, p=0.44). In the IPC 
group the remission rate was slightly higher than the response 
rate, and this was explained by a lower baseline severity in this 
treatment arm than the pharmacotherapy arm. Nevertheless, 
the difference was not so pronounced to be clinically relevant 
and all regression models were adjusted for baseline severity. 
Age, gender and presence of a personality disorder did not 
show any effect on outcomes in both treatment groups (Table 
3). On the other hand, response and remission rates were in-
fluenced by baseline severity in the IPC group (Table 3).
Serotonin-related polymorphisms
None of the investigated polymorphisms showed to affect 
response and remission rates neither in the IPC nor in the an-
tidepressant treated group (Table 3 and 4). One-way ANOVA 
confirmed no effect of genetic variants on clinical outcomes 
after adjusting for center and baseline severity in the IPC 
group (data not shown). On the other hand, in the whole sam-
ple a trend of association between rs7997012 (HTR2A) and 
remission was observed (χ2=5.78, df=2, p=0.056), confirmed 
by one-way ANOVA adjusted for baseline severity and centre 
(F=2.93, df=2, p=0.057). Subjects carrying the AA genotype 
showed lower 8-week improvement of the HDRS score (38.74± 
33.89) compared to those carrying the GA genotype (58.13± 
27.91) and the GG genotype (55.67±27.33). 
No major gender-stratification effect was detected. Howev-
er, HTR2A rs2224721 showed a trend of interaction with gen-
der: in the IPC group males carrying the A allele showed low-
er HDRS improvement than those carrying the C allele, while 
this difference was not observed in females (F=6.38, df=1, p= 
0.01). Indeed, the HDRS improvement (%) at week 8 was 
42.64±17.02 in males carrying the A allele, while it was 52.27± 
11.81 in carriers of the C allele. In females instead, the im-
provement was similar for both alleles (C: 51.95±21.15; A: 
55.85±27.73). A trend in the same direction was found in the 
antidepressant treated group (F=3.96, df=1, p=0.048) as well 
as in the whole sample (F=2.79, df=1, p=0.096). 
DISCUSSION
The present study investigated the efficacy of a brief struc-
Table 3. Distribution of clinical variables according to response and remission status, for each treatment group
Responders Non responders Stat Remitters Non remitters Stat
IPC
Age   40.96±14.90   49.13±17.15 t =-1.57, CI=-18.78-2.46, 
p=0.13
  44.68±15.66   42.69±17.61 t=0.35, CI=-9.83-13.82, 
p=0.73
Gender (F/M) 15/11 10/6 χ2=2e-04, df=1,
p=0.99
17/12 8/5 χ2=0.03, df=1,
p=0.87
Baseline severity  
  (HDRS)
17.54±3.75 14.56±4.07 t=2.37, CI=0.41-5.54, 
p=0.024
15.34±3.12 18.77±5.09 t=-2.25, CI=-6.65-0.20, 
p=0.039
Personality disorder 
  (yes/no)*
4/8 4/4 χ2=0.08, df=1,
p=0.78
7/10 1/2 χ2=0.15, df=1,
p=0.70
Antidepressants
Age   53.79±18.43   53.89±17.70 t=-0.03, CI=-7.56-7.37, 
p=0.98
  53.54±18.80   54.24±17.20 t=-0.19, CI=-7.87-6.46, 
p=0.85
Gender (F/M) 42/25 28/8 χ2=1.81, df=1,
p=0.18
39/23 31/10 χ2=1.29, df=1,
p=0.26
Baseline severity  
  (HAM-D)
18.46±4.76 17.39±4.04 t=1.21, CI=-0.70-2.84,
p=0.23
17.74±4.98 18.61±3.74 t=-0.01, CI=-2.58-0.84, 
p=0.32
Personality disorder 
  (yes/no)*
14/28 11/14 χ2=0.37, df=1,
p=0.54
14/26 11/16 χ2=0.04, df=1,
p=0.83
*available for only 2 centers (Bologna and Torino). CI: 95% confidence interval, HDRS: Hamilton Depression Rating Scale 21-items, IPC: in-
terpersonal counseling, Stat: statistics
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tured psychological intervention, IPC, versus the more widely 
used antidepressant drug treatment, together with the effect 
of five serotonin-related polymorphisms on clinical outcomes 
in both treatment groups as well as in the whole sample. No 
differences in response, remission rates and percent of im-
provement at week 8 were found between the two treatment 
arms (Table 2), also adjusting for age, baseline severity and 
center. Our findings support the efficacy of IPC in the treat-
ment of mild-moderate MDD, suggesting it is a useful alter-
native to antidepressants. The choice of IPC may be particu-
larly useful in patients with higher risk of drug-related adverse 
events, like the elderly (because of polypharmacy and chronic 
diseases), pregnant women and in post-partum MDD, as 
confirmed by the marginally higher number of discontinua-
Table 4. Response and remission rates at week 8 for each genotype and treatment group
ICP (N=40) Antidepressants (N=102)
COMT rs4680 AA AG GG Stat AA AG GG Stat
Response
Yes 5 (20) 16 (64) 4 (16) χ2=3.07, df=2,
p=0.21
12 (18.18) 38 (57.58) 16 (24.24) χ2=0.98, df=2,
p=0.61No 5 (33.33) 10 (66.67) 0 (0) 6 (16.67) 18 (50.00) 12 (33.33)
Remission
Yes 6 (21.43) 19 (67.86) 3 (10.71) χ2=0.64, df=2,
p=0.73
12 (19.67) 36 (59.02) 13 (21.31) χ2=2.90, df=2,
p=0.23No 4 (33.33) 7 (58.33) 1 (8.33) 6 (14.63) 20 (48.78) 15 (31.71)
HTR1A rs6295 CC CG GG CC CG GG
Response
Yes 7 (28.00) 13 (52.00) 5 (20.00) χ2=0.01, df=2,
p=0.9954
13 (19.70) 28 (42.42) 25 (37.88) χ2=0.93, df=2,
p=0.63No 4 (23.53) 8 (47.06) 3 (17.65) 10 (27.78) 13 (36.11) 13 (36.11)
Remission
Yes 9 (32.14) 14 (50.00) 5 (17.86) χ2=1.06, df=2,
p=0.59
13 (21.31) 24 (39.34) 24 (39.34) χ2=0.31, df=2,
p=0.86No 2 (16.67) 7 (58.33) 3 (25.00) 10 (24.39) 17 (41.46) 14 (34.15)
HTR2A rs2224721 AA CA CC AA CA CC
Response
Yes 1 (4.00) 10 (40.00) 14 (56.00) χ2=0.39, df=2,
p=0.82
6 (9.09) 20 (30.30) 40 (60.61) χ2=3.91, df=2, 
p=0.14No 1 (6.67) 7 (46.67) 7 (46.67) 2 (5.56) 18 (50.00) 16 (44.44)
Remission
Yes 2 (7.14) 10 (35.71) 16 (57.14) χ2=2.25, df=2,
p=0.32
5 (8.20) 22 (36.01) 34 (55.74) χ2=0.10, df=2,
p=0.95No 0 (0) 7 (58.33) 5 (41.67) 3 (7.32) 16 (39.02) 22 (53.66)
HTR2A rs7997012 AA GA GG AA GA GG
Response
Yes 1 (4.00) 10 (40.00) 14 (56.00) χ2=2.42, df=2,
p=0.30
6 (9.09) 29 (43.94) 31 (46.97) χ2=2.33, df=2,
p=0.31No 2 (13.33) 3 (17.65) 10 (66.67) 7 (19.44) 15 (41.67) 14 (38.89)
Remission
Yes 1 (3.57) 11 (39.29) 16 (57.14) χ2=3.37, df=2,
p=0.19
5 (8.20) 28 (45.90) 28 (45.90) χ2=2.84, df=2, 
p=0.24No 2 (16.67) 2 (16.67) 8 (66.67) 8 (19.51) 16 (39.02) 17 (41.46)
SLC6A4 rs4251417 AA GA GG AA GA GG
Response
Yes 1 (4.00) 7 (28.00) 17 (68.00) χ2=0.64, df=2,
p=0.72
1 (1.54) 17 (26.15) 47 (72.31) χ2=2.73, df=2,
p=0.26No 0 (0) 4 (26.67) 11 (73.33) 0 (0) 5 (13.89) 31 (86.11)
Remission
Yes 1 (3.57) 9 (32.14) 18 (64.29) χ2=1.59, df=2, 
p=0.45
1 (1.68) 15(25.00) 44 (73.33) χ2=1.67, df=2, 
p=0.43No 0 (0) 2 (16.67) 10 (83.33) 0 (0) 7 (17.07) 34 (82.93) 
IPC: interpersonal counseling, COMT: catechol-O-methyltransferase, HTR1A: 5-hydroxytryptamine (serotonin) receptor 1A, HTR2A: 
5-hydroxytryptamine (serotonin) receptor 2A, SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
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tions in the antidepressant group. Only in the IPC arm, re-
sponders showed higher HDRS scores at baseline, while the 
opposite picture was seen for remitters (Table 3). Also previ-
ous studies reported contradictory results about the associa-
tion between baseline severity score and antidepressant treat-
ment outcome, which do not allow a clear interpretation.52 
Anyway, baseline severity scores per se are probably not a pre-
dictor of clinical outcome, but possibly only in particular 
groups of patients (e.g., presence of dysfunctional personality 
traits53) or depending from the type of treatment.54
None of the investigated serotonin-related variants was 
found associated with clinical outcomes, either in the antide-
pressant or in the IPC group (Table 4 and 5) also adjusting re-
sults for confounding variables (site of recruitment and base-
Table 5. Response and remission rates at week 8 for each allele and treatment group
ICP (N=40) Antidepressants (N=102)
COMT rs4680 A G Stat A G Stat
Response
Yes 26 (52.00) 24 (48.00) χ2=1.10, df=1, 
p=0.29
62 (46.97)   70 (53.03) χ2=0.34, df=1, 
p=0.56No 20 (66.67) 10 (33.33) 30 (41.67)   42 (58.33)
Remission
Yes 31 (55.36) 25 (44.64) χ2=0.12, df=1, 
p=0.73
60 (49.18)   62 (50.82) χ2=1.65, df=1, 
p=0.20No 15 (62.50)   9 (37.50) 32 (39.02)   50 (60.98)
HTR1A rs6295 C G C G
Response
Yes 27 (54.00) 23 (46.00) χ2=0.03, df=1, 
p=0.86
54 (40.90)   78 (59.10) χ2=0.28, df=1, 
p=0.60No 16 (53.33) 14 (46.67) 33 (45.83)   39 (54.17)
Remission
Yes 32 (57.14) 24 (42.86) χ2=0.47, df=1, 
p=0.49
50 (40.98)   72 (59.02) χ2=0.20, df=1, 
p=0.66No 11 (45.83) 13 (54.17) 37 (45.12)   45 (54.88)
HTR2A rs2224721 A C A C
Response
Yes 12 (24.00) 38 (76.00) χ2=0.11, df=1, 
p=0.74
32 (24.24) 100 (75.76) χ2=0.66, df=1, 
p=0.42No   9 (30.00) 21 (70.00) 22 (30.56)   50 (69.44)
Remission
Yes 14 (25.00) 42 (75.00) χ2=0.01, df=1, 
p=0.91
32 (26.23)   90 (73.77) χ2=0.004, df=1, 
p=0.95No   7 (29.17) 17 (70.83) 22 (26.83)   60 (73.17)
HTR2A rs7997012 A G A G
Response
Yes 12 (24.00) 38 (76.00) χ2=0.04, df=1, 
p=0.84
41 (31.06)   91 (68.94) χ2=1.37, df=1, 
p=0.24No   7 (23.33) 23 (76.67) 29 (40.28)   43 (59.72)
Remission
Yes 13 (23.21) 43 (76.79) χ2=0.01, df=1, 
p=0.91
38 (31.15)   84 (68.85) χ2=1.02, df=1, 
p=0.31No   6 (25.00) 18 (75.00) 32 (39.02)   50 (60.98)
SLC6A4 rs4251417 A G A G
Response
Yes   9 (18.00) 41 (82.00) χ2=0.05, df=1, 
p=0.81
19 (14.62) 111 (85.38) χ2=1.92, df=1, 
p=0.17No   4 (13.33) 26 (86.67) 5 (6.94)   67 (93.06)
Remission
Yes 11 (19.64) 45 (80.36) χ2=0.86, df=1, 
p=0.35
17 (14.17) 103 (85.83) χ2=0.99, df=1, 
p=0.32No 2 (8.33) 22 (91.67) 7 (8.54)   75 (91.46)
IPC: interpersonal counseling, COMT: catechol-O-methyltransferase, HTR1A: 5-hydroxytryptamine (serotonin) receptor 1A, HTR2A: 
5-hydroxytryptamine (serotonin) receptor 2A, SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
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line severity-IPC group). The polymorphisms of interest 
were investigated also in the whole sample, since similar me-
chanisms of action are supposed to lay behind the clinical ef-
ficacy of both antidepressant drugs and psychotherapy.44,45 In 
the whole sample a trend of lower remission was found in 
subjects carrying the AA genotype of rs7997012, as well as 
lower percent HDRS improvement at week 8 was observed in 
this group (38.74±33.89 vs. 58.13±27.91 of the GA and 55.67± 
27.33 of the GG genotypes). 
The studied polymorphisms were carefully selected in ac-
cordance with the known biological function and previous 
pharmacogenetic findings. The role of COMT rs4680 and 
HTR1A rs6295 has been repeatedly studied, but with incon-
sistent results, particularly in regard to the identification of 
the risk allele.6 On the other hand, HTR2A rs2224721 and 
SLC6A4 rs4251417 are new candidates, since the former was 
one of the best pharmacogenetic findings of the GENDEP 
study14 but confirmations are lacking, while the latter has not 
been studied yet as predictor of antidepressant efficacy despite 
of its key position. Despite our overall negative findings, a tr-
end of association with HTR2A variants was detected, suppo-
rting the quite replicated evidence which suggest a role of the 
gene in antidepressant effect.10-12 Indeed, HTR2A rs7997012 
A allele was a confirmed predictor of citalopram response in 
the STAR*D study,10,11 while in the GENDEP study an associ-
ation in the opposite direction was reported,12 in line with our 
results; finally, some smaller studies reported negative find-
ings.13-16 The other interesting result involving HTR2A is a 
detrimental effect of rs2224721 A allele only in males, who 
showed a lower HDRS improvement compared to males car-
rying the C allele. The finding supports the hypothesis of a 
gender-stratification effect affecting the association between 
genetic variants and antidepressant outcome, as several lines 
of evidence previously suggested.55
Nevertheless, the overall negative findings provided by the 
present study further suggest that the role of these polymor-
phisms in antidepressant efficacy is probably modest, i.e., the 
explained variance in response is probably low considering 
only one polymorphism at a time. For example, rs2224721 
explained only about the 1.1% of the variance in response to 
escitalopram in the GENDEP study, despite it was one of the 
SNPs with higher evidence of association14 and in our study 
we could not detect explained variances lower than 2.2%. In-
deed, the small sample size is the major limitation of the pres-
ent study, and also the multicenter nature may introduce bi-
ases, but we used all standard methods to avoid center effects, 
and consequently no center stratification effect was observed. 
The lack of a combined treatment arm may be seen as a limi-
tation, but the available evidence suggest no clear benefit of 
combined treatment over monotherapy in mild-moderate 
MDD,4 thus no further useful information could be derived 
from this analysis. As for strengths, despite the relative small 
sample size, the present study is the first to investigate the role 
of serotonin-related genetic variants in both psychotherapy 
and antidepressant treated MDD patients. Serotoninergic 
genes indeed are a priori optimal candidates for both types of 
treatment, since the emerging evidence of similar underlying 
neurobiological basis.44,45,56 Some differences in baseline clini-
cal characteristics were observed between the antidepressant 
and IPC treated groups (Table 2), this also explains the appar-
ently opposite effects of baseline severity on outcome for IPC, 
but all regression models comparing the two groups were ad-
justed for the effect of these confounding variables.
Our results suggest no major role of rs7997012 and rs2224 
721 (HTR2A), rs6295 (HTR1A), rs4251417 (SLC6A4) and 
rs4680 (COMT) in both IPC and antidepressant efficacy. 
Considering both treatment arms, a trend of worse outcome 
was detected in carriers of the rs7997012 AA genotype 
(HTR2A gene), while in all treatment groups as well as the 
combined sample males carrying the A allele of rs2224721 
(HTR2A gene) showed a trend of worse outcome, that was 
not observed in females. The present study also concluded 
that IPC, a brief structured psychological intervention, shows 
similar efficacy to antidepressant drugs in mild-moderate 
MDD, confirming its clinical usefulness when pharmacologi-
cal treatments are contraindicated, refused or not tolerated.
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